Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
D. Sugiyama,H. Nishikawa,10 Auteurs,S. Sakaguchi
2013 · DOI: 10.1073/pnas.1316796110
Proceedings of the National Academy of Sciences of the United States of America · 602 citations
TLDR
Cell-depleting anti-CCR4 mAb therapy is instrumental for evoking and enhancing tumor immunity in humans via selectively removing effector-type FOXP3+ Treg cells by selectively depleting eTreg cells.